Avista Capital Partners has agreed to acquire Marlborough, Massachusetts-based Solmetex, a provider of amalgam separators and other waste compliance products. No financial terms were disclosed. Piper ...
CHICAGO, Oct. 14, 2025 /PRNewswire/ -- GTCR, a leading private equity firm, announced today the simultaneous signing and closing of a strategic, structured minority investment in Solmetex (the ...
NEW YORK, March 19, 2025 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading New York-based private equity firm focused exclusively on healthcare, is pleased to announce the successful ...
MARLBOROUGH, Mass. & VANCOUVER, Wash.--(BUSINESS WIRE)--Solmetex, LLC, a leading provider of dental consumables and equipment, today announced the acquisition of ReLeaf, an innovator in hands-free, ...
For Solmetex, the purchase expands its portfolio of dental waste products and programs for its doctor partners and communities they serve. "We anticipate a high growth of the amalgam separator ...
Solmetex’s existing backers are Agic Capital, Avista Healthcare Partners, and Gemini Investors Phil Fraser serves as CEO of ReLeaf Solmetex, which is backed by GTCR, has acquired ReLeaf, a Vancouver, ...
NEW YORK, Jan. 19, 2021 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, last week completed its previously announced acquisition of ...
Solmetex has received a utility patent and two design patents for its NXT amalgam separator system. The utility patent, U.S. patent No. 10,646,313 B2, is for a dental amalgam separation system that ...
MARLBOROUGH — A local dental supply company will not be consolidating all of its offices in Marlborough anytime soon, despite attempts by the city to lure it to the community through a Tax Increment ...
Solmetex, LLC, a leading provider of dental consumables and equipment, today announced the acquisition of ReLeaf, an innovator in hands-free, high-volume evacuation for hygiene and clinical procedures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results